Prolastin, Prolastin-C Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Prolastin, Prolastin-C market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed in the historic period can be attributed to increased awareness of alpha-1 antitrypsin deficiency (AATD), a rise in the prevalence of chronic obstructive pulmonary disease (COPD), enhanced clinical research on lung disease management, a higher number of AATD diagnoses, and increased funding for rare disease treatments.

Market growth during the forecast period is driven by factors such as a growing aging population, rising incidence of lung diseases, greater awareness and diagnosis of AATD, increased interest in personalized medicine, and ongoing clinical trials and research for better therapies. Key trends during the forecast period include the growing adoption of combination therapies, a stronger focus on long-term patient monitoring, expanding product offerings and treatment formats, higher investment in clinical trials for augmentation therapies, and the integration of digital health solutions.

The increase in incidence of respiratory infections is expected to propel the growth of the prolastin and prolastin-C market going forward. Respiratory infections, caused by pathogens such as viruses, bacteria, and fungi, affect the respiratory system, including the lungs and airways. Factors such as emerging viral strains, environmental pollution, and seasonal changes contribute to a rise in these infections. Prolastin and Prolastin-C are forms of alpha-1 antitrypsin (AAT) replacement therapy, which help manage respiratory diseases related to alpha-1 antitrypsin deficiency (AATD) by replenishing the deficient AAT protein, reducing lung inflammation, and improving lung function. For instance, in November 2023, the Bureau of Labor Statistics reported an increase in respiratory illnesses among private industry workers, which is expected to drive demand for Prolastin and Prolastin-C. Therefore, the increase in incidence of respiratory infections is driving the growth of the prolastin and prolastin-C market.

The increasing research and development expenditure is expected to propel the growth of the prolastin and prolastin-C market going forward. Research and development (R&D) expenditure refers to financial investments made by governments and private sectors to develop new therapies, improve existing treatments, and foster innovation. Increases in R&D expenditure contribute to advanced clinical trials, formulation improvements, and enhanced patient outcomes. For instance, in July 2024, the Department of Health and Social Care reported that the UK invested $10.98 billion in pharmaceutical R&D in 2022. This expenditure helps to advance therapies like Prolastin and Prolastin-C. Therefore, the increasing R&D expenditure is driving the growth of the Prolastin and Prolastin-C market.

A key trend in the prolastin and prolastin-C market is the focus on clinical trials to assess the safety and effectiveness of these pharmaceuticals. Clinical trials play a crucial role in evaluating new drugs and treatments. For instance, in July 2023, Grifols SA announced the enrollment of 339 patients in the SPARTA phase 3 clinical trial to evaluate Prolastin-C's efficacy in slowing lung tissue loss in AATD patients. Such trials are essential for advancing the use of Prolastin and Prolastin-C in treating alpha-1 antitrypsin deficiency and improving patient outcomes.

Key player operating in the prolastin, prolastin-c market is Grifols SA.

North America was the largest region in the prolastin or prolastin-C market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in prolastin, prolastin-C report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the prolastin, prolastin-C market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Prolastin is a purified human alpha-1 antitrypsin protein replacement therapy used to manage alpha-1 antitrypsin deficiency. Prolastin-C is a specific formulation of alpha-1 antitrypsin aimed at preventing the progression of lung disease in patients with alpha-1 antitrypsin deficiency. Both products help reduce the risk of lung damage and related complications in individuals with this deficiency.

The primary formulations of prolastin and prolastin-C are available in 20 mL and 40 mL, catering to varying patient needs. The primary indications for these products include Alpha-1 antitrypsin deficiency, respiratory health, chronic lung disease, and genetic disorders, all of which are crucial areas of patient care. These treatments are administered in settings such as hospitals and pharmacies, ensuring proper access and delivery.

The prolastin, prolastin-C market research report is one of a series of new reports that provides prolastin, prolastin-C market statistics, including prolastin, prolastin-C industry global market size, regional shares, competitors with a prolastin, prolastin-C market share, detailed prolastin, prolastin-C market segments, market trends and opportunities, and any further data you may need to thrive in the prolastin, prolastin-C industry. This prolastin, prolastin-C market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prolastin, prolastin-C market consists of sales of pre-filled syringes, customized dosing kits, and lyophilized powder formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.